IMP-GMP specific cytosolic 5'-nucleotidase regulates nucleotide pool and prodrug metabolism

Biochim Biophys Acta. 2015 Jul;1850(7):1354-61. doi: 10.1016/j.bbagen.2015.03.017. Epub 2015 Apr 7.

Abstract

Background: Type II cytosolic 5'-nucleotidase (cN-II) catalyzes the hydrolysis of purine and, to some extent, of pyrimidine monophosphates. Recently, a number of papers demonstrated the involvement of cN-II in the mechanisms of resistance to antitumor drugs such as cytarabine, gemcitabine and fludarabine. Furthermore, cN-II is involved in drug resistance in patients affected by hematological malignancies influencing the clinical outcome. Although the implication of cN-II expression and/or activity appears to be correlated with drug resistance and poor prognosis, the molecular mechanism by which cN-II mediates drug resistance is still unknown.

Methods: HEK 293 cells carrying an expression vector coding for cN-II linked to green fluorescent protein (GFP) and a control vector without cN-II were utilized. A highly sensitive capillary electrophoresis method was applied for nucleotide pool determination and cytotoxicity exerted by drugs was determined with 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay.

Results: Over-expression of cN-II causes a drop of nucleoside triphosphate concentration and a general disturbance of nucleotide pool. Over-expressing cells were resistant to fludarabine, gemcitabine and cytarabine independently of cN-II ability to hydrolyze their monophosphates.

Conclusions: An increase of cN-II expression is sufficient to cause both a general disturbance of nucleotide pool and an increase of half maximal inhibitory concentration (IC50) of the drugs. Since the monophosphates of cytarabine and gemcitabine are not substrates of cN-II, the protection observed cannot be directly ascribed to drug inactivation.

General significance: Our results indicate that cN-II exerts a relevant role in nucleotide and drug metabolism through not only enzyme activity but also a mechanism involving a protein-protein interaction, thus playing a general regulatory role in cell survival.

Sentence: Resistance to fludarabine, gemcitabine and cytarabine can be determined by an increase of cN-II both through dephosphorylation of active drugs and perturbation of nucleotide pool.

Keywords: Chemotherapy; Cytarabine; Fludarabine; Gemcitabine; Resistance; cN-II.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 5'-Nucleotidase / genetics
  • 5'-Nucleotidase / metabolism*
  • Antineoplastic Agents / metabolism*
  • Antineoplastic Agents / pharmacology
  • Cell Survival / drug effects
  • Cell Survival / genetics
  • Cytarabine / metabolism
  • Cytarabine / pharmacology
  • Deoxycytidine / analogs & derivatives
  • Deoxycytidine / metabolism
  • Deoxycytidine / pharmacology
  • Dose-Response Relationship, Drug
  • Drug Resistance / genetics
  • Gemcitabine
  • Green Fluorescent Proteins / genetics
  • Green Fluorescent Proteins / metabolism
  • Guanosine Monophosphate / metabolism
  • HEK293 Cells
  • Humans
  • Immunoblotting
  • Inosine Monophosphate / metabolism
  • Nucleotides / metabolism*
  • Phosphorylation / drug effects
  • Prodrugs / metabolism*
  • Prodrugs / pharmacology
  • Substrate Specificity
  • Vidarabine / analogs & derivatives
  • Vidarabine / metabolism
  • Vidarabine / pharmacology

Substances

  • Antineoplastic Agents
  • Nucleotides
  • Prodrugs
  • Cytarabine
  • Deoxycytidine
  • Inosine Monophosphate
  • Green Fluorescent Proteins
  • Guanosine Monophosphate
  • 5'-Nucleotidase
  • Vidarabine
  • fludarabine
  • Gemcitabine